Feladilimab
Sponsors
GlaxoSmithKline
Conditions
Multiple MyelomaNeoplasmsNeoplasms, Head and Neck
Phase 1
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
CompletedNCT03693612
Start: 2018-11-26End: 2021-09-16Updated: 2024-08-28
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM
Active, not recruitingNCT07217119
Start: 2019-11-26End: 2027-03-11Updated: 2025-10-15
Phase 2
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)
CompletedNCT03739710
Start: 2019-01-24End: 2024-05-02Updated: 2025-06-15
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Active, not recruitingNCT04126200
Start: 2019-10-07End: 2027-03-11Updated: 2025-11-06
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1
CompletedNCT05553808
Start: 2019-01-24End: 2021-09-23Updated: 2023-01-19
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2
TerminatedNCT06790303
Start: 2021-03-04End: 2021-09-23Updated: 2025-06-04
Phase 3
Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
TerminatedNCT04128696
Start: 2019-11-21End: 2023-06-20Updated: 2024-07-10
Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
TerminatedNCT04428333
Start: 2020-08-12End: 2023-09-19Updated: 2024-10-09